Bleeding Outcomes after Left Atrial Appendage Closure Compared with Long-Term Warfarin A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience

JACC: Cardiovascular Interventions

Volumn 8, Issue 15, 2015, Pages 1925-1932

  Price, Matthew J ^a   Reddy, Vivek Y ^b   Valderrábano, Miguel ^c   Halperin, Jonathan L ^b   Gibson, Douglas N ^a   Gordon, Nicole ^d   Huber, Kenneth C ^e   Holmes, David R ^f  

^a SCRIPPS CLINIC   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e ST LUKE S HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

Author keywords

atrial fibrillation; bleeding; left atrial appendage; left atrial appendage closure; WATCHMAN

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM APPENDAGE CLOSURE; HEART SURGERY; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX DIFFERENCE; SURVIVAL; THROMBOEMBOLISM; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DEVICES; EMBOLIC PROTECTION DEVICE; HEART ATRIUM APPENDAGE; HEART CATHETERIZATION; HEMORRHAGE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ODDS RATIO; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIAL; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; EMBOLIC PROTECTION DEVICES; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84952874862     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.08.035     Document Type: Article

References (25)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
2. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
3. M.W. Cullen, S. Kim, J.P. Piccini Sr., and et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Circ Cardiovasc Qual Outcomes 6 2013 461 469
4. V.L. Baczek, W.T. Chen, J. Kluger, and C.I. Coleman Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis BMC Fam Pract 13 2012 5
5. E.C. O'Brien, D.N. Simon, L.A. Allen, and et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Am Heart J 168 2014 487 494
6. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
7. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
8. S.J. Connolly, J. Eikelboom, C. Joyner, and et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
9. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
10. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
11. J.L. Blackshear, and J.A. Odell Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation Ann Thorac Surg 61 1996 755 759
12. M.J. Price, and M. Valderrabano Left atrial appendage closure to prevent stroke in patients with atrial fibrillation Circulation 130 2014 202 212
13. D.R. Holmes Jr., S. Kar, M.J. Price, and et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial J Am Coll Cardiol 64 2014 1 12
14. V.Y. Reddy, H. Sievert, J. Halperin, and et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial JAMA 312 2014 1988 1998
15. D.R. Holmes, V.Y. Reddy, Z.G. Turi, and et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial Lancet 374 2009 534 542
16. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
17. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
18. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
19. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
20. M.I. Aguilar, R. Hart, and L.A. Pearce Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks Cochrane Database Syst Rev 2007 CD006186
21. M.J. Price, D.N. Gibson, S.J. Yakubov, and et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. Transcatheter LAA Ligation Consortium J Am Coll Cardiol 64 2014 565 572
22. M.A. Miller, S.R. Gangireddy, S.K. Doshi, and et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device Heart Rhythm 11 2014 1853 1859
23. S. Connolly, J. Pogue, R. Hart, et al. for the ACTIVE Writing Group of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
24. V.Y. Reddy, S. Mobius-Winkler, M.A. Miller, and et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) J Am Coll Cardiol 61 2013 2551 2556
25. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 e76